Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge

Summary

This observational study aims to comprehensively characterize immune-related adverse events (irAEs) occurring during immune checkpoint inhibitor (ICI) therapy in cancer patients and to evaluate the safety and clinical outcomes of ICI rechallenge following irAE resolution. In addition to detailed clinical data collection, the study incorporates biospecimen acquisition, when clinically indicated and feasible, including peripheral blood and organ-specific specimens (e.g., bronchoalveolar lavage fluid for ICI-related pneumonitis, liver biopsy tissue for ICI-related hepatitis, and other relevant clinical specimens). These samples will support exploratory immunologic and molecular analyses to better understand mechanisms underlying irAE development, resolution, and recurrence after rechallenge. This study is designed to generate real-world evidence to improve risk stratification, toxicity management, and decision-making regarding immunotherapy continuation or re-initiation.

Eligibility

Inclusion Criteria:

* Adults (≥18 years old) with a diagnosis of malignant tumor.
* Received treatment with immune checkpoint inhibitors (including anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 agents).
* Developed documented immune-related adverse events (irAEs) during ICI therapy, as determined by treating physicians.
* Availability of clinical data for evaluation of irAE characteristics and outcomes.

Exclusion Criteria:

* Patients receiving ICIs outside of the participating institution without accessible clinical records.
* Insufficient clinical information to determine irAE diagnosis or outcomes.
* Patients who decline use of their clinical data or biospecimens, when applicable.

Conditions2

Interventions1

Related trials

• A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis — Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
• Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients — Hospital Universitario Araba
• Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma — Anhui Provincial Hospital
• Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors — University Hospital, Basel, Switzerland

Browse More Trials